ArticleClinical rheumatology2016
Evaluation of subclinical inflammation in familial Mediterranean fever patients: relations with mutation types and attack status: a retrospective study.
Article in Clinical rheumatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Practical considerations for monitoring patients with familial Mediterranean fever: review of evidence and expert opinion.Frontiers in immunology · 2026Review
- Old and New Biomarkers in Idiopathic Recurrent Acute Pericarditis (IRAP): Prognosis and Outcomes.Current cardiology reports · 2025Review
- Inflammatory biomarker analysis confirms reduced disease severity in heterozygous patients with familial Mediterranean fever.RMD open · 2024Article
- Pan-Immune-Inflammation Value Could Be a New Marker to Predict Amyloidosis and Disease Severity in Familial Mediterranean Fever.Diagnostics (Basel, Switzerland) · 2024Article
- Patient Experiences and Challenges in the Management of Autoinflammatory Diseases-Data from the International FMF & AID Global Association Survey.Journal of clinical medicine · 2024Article
- Anxiety and depression among patients with familial Mediterranean fever.Zeitschrift fur Rheumatologie · 2024Article
- Early Versus Late Onset Familial Mediterranean Fever: Similarities, Discrepancies, and the Value of Neutrophil to Lymphocyte Ratio in Detecting Autoinflammation.Journal of clinical practice and research · 2024Article
- Relationship between sacroiliitis and inflammatory markers in familial Mediterranean fever.Revista da Associacao Medica Brasileira (1992) · 2024Article
- Importance of hematological markers in familial Mediterranean fever in terms of disease severity and amyloidosis.Rheumatology international · 2023Article
- Is apical lung fibrosis really associated with familial Mediterranean fever?Clinical rheumatology · 2023Article
- Factors affecting patient-acceptable symptom states and treatment decision in familial Mediterranean fever.Turkish journal of medical sciences · 2022Article
- Assessment of vascular damage in children and young adults with Familial Mediterranean Fever.Rheumatology international · 2022Observational
- Nodular Lymphocyte-Predominant Hodgkin Lymphoma in a Patient with Familial Mediterranean Fever.Mediterranean journal of hematology and infectious diseases · 2022Article
- The Platelet-to-Lymphocyte Ratio as an Inflammatory Marker in Rheumatic Diseases.Annals of laboratory medicine · 2019Review
- Familial Mediterranean Fever: Assessing the Overall Clinical Impact and Formulating Treatment Plans.Mediterranean journal of hematology and infectious diseases · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Familial Mediterranean fever (FMF) is an autosomal recessive autoinflammatory disease of childhood and adulthood. Development of systemic amyloidosis and frequent attack influence quality of life and survival. There is sporadic evidence indicating subclinical inflammation in patients with FMF. We aimed to assess subclinical inflammation using neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and C-reactive protein (CRP) in pediatric patients with FMF in the attack-free period. In this retrospective study, we reviewed the files of all FMF patients in our pediatric rheumatology outpatient clinic in a tertiary center and enrolled those with sufficient clinical and laboratory data. We also enrolled 73 controls. We grouped the patients according to being in attack period or attack-free period. We compared CRP, NLR, PLR, and WBC (white blood cell) levels between different mutations and polymorphisms. We also compared patients in the attack period with those in attack-free period. We enrolled 61 patients in attack period, 509 patients in attack-free period, and 73 controls. There was no difference between patients with different mutations with respect to NLR or PLR levels in the attack-free period. However, CRP levels were higher in patients with homozygous exon 10 mutations, especially those with homozygous M694V mutations compared with other mutations. However, CRP levels were mostly normal in these patients. Our data are against the reported fact that patients with FMF have higher NLR or PLR levels in attack-free periods. However, CRP levels were higher in the presence of homozygous exon 10 mutations (in particular homozygous M694V mutations).
Indexed as
Identifiers
27106545What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.